Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Heart Failure 3Cardiotoxicity 2Breast Neoplasms 2Thyroid cancer, medullary 1Neoplasms, Second Primary 1Carcinoma, Medullary 1Breast Diseases 1

Interventions

Everolimus 3Capecitabine 3lutetium Lu 177 dotatate 2lenvatinib 2cabozantinib 2Thyroidectomy 2Temozolomide 2Sorafenib 2Magnetic Resonance Spectroscopy 2High-Energy Shock Waves 2veliparib 1vatalanib 1vandetanib 1temsirolimus 1selpercatinib 1sacubitril and valsartan sodium hydrate drug combination 1ponatinib 1pentetreotide 1pasireotide 1gallium Ga 68 dotatate 1fluorodopa F 18 1fludarabine 1cemiplimab 1Vinorelbine 1Thalidomide 1Surgical Procedures, Operative 1Sunitinib 1Specimen Handling 1Sirolimus 1Semaxinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Medullary × sacubitril and valsartan sodium hydrate drug combination × Clear all
NCT03647657 2022-02-10

177Lu-PP-F11N in Combination With Sacubitril for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer

University Hospital, Basel, Switzerland

Phase EARLY_PHASE1 Completed
8 enrolled
EndocrineHead & Neck

Thyroid cancer, medullary, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡